Syneron Medical (ELOS) to Acquire TransPharma Medical in $3.6M Deal
Tweet
Share
E-mailGet Alerts ELOS Hot Sheet
Join SI Premium – FREE
Syneron Medical Ltd. (Nasdaq: ELOS) has signed a definitive agreement to acquire substantially all the assets of TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transdermal drug delivery technology.
Under terms of the agreement, Syneron will acquire substantially all the assets of TransPharma, including its patent portfolio, for approximately $3.6 million in cash. The acquisition is subject to customary closing conditions.
Under terms of the agreement, Syneron will acquire substantially all the assets of TransPharma, including its patent portfolio, for approximately $3.6 million in cash. The acquisition is subject to customary closing conditions.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein on whether Hershey (HSY) could eventually step up to buy Mondelez (MDLZ)
- Myriad Uranium completes acquisition of Rush Rare Metals
- LivePerson extends special meeting deadline for SoundHound AI merger vote
Create E-mail Alert Related Categories
Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
